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ABSTRACT
Objective: Fosfomycin is an alternative drug for treatment of uncomplicated urinary tract infections. This study aimed 
to investigate in vitro activity of fosfomycin against methicillin-resistant Staphylococcus aureus (MRSA), methicillin-
resistant coagulase negative staphylococci (MRCoNS), vancomycin-resistant Enterococcus faecium (VR E. faecium), Esch-
erichia coli, Klebsiella pneumoniae, and Enterobacter isolates.
Methods: Clinical isolates of MRSA, MRCoNS, E. coli, K. pneumoniae and Enterobacter spp. and VRE isolates which were 
isolated from rectal swaps were identified with Vitek 2 Compact (Biomeriux, France) and BD Phoenix (BD USA) auto-
mated systems. The Kirby-Bauer disc diffusion method was used to determine the susceptibility to fosfomycin. 
Results: All the MRSA (n=40), MRCoNS (n=40), and VR E. faecium (n=62) isolates were susceptible to fosfomycin. The 
fosfomycin susceptibility rates for E. coli, K. pneumoniae, and Enterobacter spp. were 97.5% (39 of 40), 97.3% (36 of 37), 
and 86.9% (20 of 23), respectively. One (2.7%) isolate of K. pneumoniae and three (13.1%) isolates of Enterobacter spp. 
showed intermediate susceptibility to fosfomycin. Resistance to fosfomycin was detected in only one (2.5%) isolate of 
E. coli.
Conclusion: Based on the results of our study, fosfomycin is highly active against a collection of several gram-positive 
and gram-negative bacteria, including multidrug resistant isolates, and is an alternative drug in the treatment option. 
J Microbiol Infect Dis 2014;4(2): 55-58
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Fosfomisinin klinik izolatlara karşı in vitro etkinliği
ÖZET
Amaç: Fosfomisin komplike olmayan üriner sistem enfeksiyonlarının tedavisinde alternative bir ilaçtır. Bu çalışmanın 
amacı fosfomisinin in vitro etkinliğini, metisiline dirençli Staphylococcus aureus (MRSA), metisiline dirençli koagülaz 
negatif stafilokoklar (MRKNS), vankomisine dirençli Enterococcus faecium (VR- E. faecium), Escherichia coli, Klebsiella 
pneumoniae ve Enterobacter izolatlarında araştırmaktır. 
Yöntemler: MRSA, MRKNS, E. coli, K. pneumoniae ve Enterobacter spp. klinik örnekleri ve rektal sürüntüden izole edilen 
VRE izolatlarının tanımlanması Vitek2 Compact (Biomeriux, Fransa) ve Phoenix (BD, ABD) otomatize sisteminlerinde 
yapıldı. Fosfomisin duyarlılığı belirlenmesinde Kirby-Bauer disk difüzyon yöntemi kullanıldı. 
Bulgular: Tüm MRSA (n=40), MRKNS (n=40) ve VR- E. faecium (n=62) suşları fosfomisine duyarlı olarak saptandı. E. 
coli, K. pneumoniae ve Enterobacter spp. için fosfomisin duyarlılık oranları sırasıyla; % 97,5 (40’da 39), % 97,3 (37’de 36), 
% 86,9 (23’te 20) olarak bulundu. Bir K. pneumoniae izolatı (% 2,7) ve üç Enterobacter spp. izolatı (% 13,1) fosfomisine 
ortaduyarlı olarak saptandı. Fosfomisine karşı direnç sadece bir E. coli izolatında (% 2,5) saptandı.
Sonuçlar: Fosfomisin çoklu ilaç direncine sahip izolatlar dahil birçok Gram pozitif ve Gram negatif bakteriye karşı invitro 
yüksek etkinliğe sahiptir ve alternatif bir tedavi seçeneği olarak kullanılabilir.
Anahtar kelimeler: Fosfomisin, gram pozitif bakteri, gram negatif bakteri, antimikrobiyal ajanKaradağ A, et al., In vitro efficacy of fosfomycin  56
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INTRODUCTION
Fosfomycin is an antibiotic and a derivative of phos-
phoric acid (cis-1,2-epoxyropylphosphare acid) and 
has effect on bacterial cell wall synthesis at an ear-
lier stage than beta-lactams and glycopeptides.1-3 
Fosfomycin is recommended for the treatment of 
uncomplicated urinary system infections caused 
by  Escherichia coli and Enterococcus faecalis. 
It is also effective against various gram-negative 
and gram-positive bacteria, such as Pseudomonas 
aeruginosa, extended spectrum beta lactamase 
(ESBL), and carbapenemase-producing Enterobac-
teriaceae, as well as methicillin-resistant Staphylo-
coccus aureus.3-5 
The increasing rate of antibacterial resistance 
in Enterobactericeae limits the number of agents 
that may be used in infections caused by these 
bacteria. ESBL enzymes are important both in com-
munity-acquired and hospital-acquired isolates.6 In-
creasing antimicrobial resistance leads difficulties in 
the treatment of enterococcal infections. Glycopep-
tide resistance has become a significant problem in 
nosocomial infections.7
S. aureus is an important cause of nosocomial 
bacteremia. Coagulase-negative staphylococci are 
one of the most common sources of blood- and 
catheter-associated infections, particularly in he-
matology and oncology patients.8 Methicillin-resis-
tant staphylococci bear a staphylococcal cassette 
chromosome (Scc) in their genome that gives rise 
to resistance against methicillin, as well as other 
antimicrobials. As the beta-lactam group antimicro-
bials cannot be used in the treatment of methicillin-
resistant S. aureus (MRSA) and methicillin-resistant 
coagulase negative staphylococci (MRCoNS) infec-
tions, glycopeptides are the drug of choice.9 On the 
other hand, the detection of vancomycin-resistant 
and intermediate S. aureus strains are also of con-
cern today.10 
The increasing rate of antimicrobial resistance 
is an emerging problem. It is an important issue for 
clinicians to choose appropriate agents in treatment 
of infections by bacterium which are resistant to 
several antimicrobials. It is known fact that there is 
need to discover new treatment options and fosfo-
mycin, may be one of this options.11
In this study, we aimed to evaluate the fosfomy-
cin susceptibility of MRSA, MRCoNS, vancomycin-
resistant Enterococcus faecium (VR E. faecium), E. 
coli, K. pneumoniae, and Enterobacter spp. isolates 
from clinical specimens.
METHODS
A total of 180 non-duplicate isolates of bacterial 
species recovered from various clinical specimens 
received from different clinics were included in the 
study. The distribution of the isolates, which were 
collected between January 2011 and September 
2011, were as follows: MRSA (n=40), MRCoNS 
(n=40), E. coli (n=40), K. pneumoniae (n=37), and 
Enterobacter spp. (n=23). During the study period, 
the specimens were routinely inoculated onto 5% 
sheep blood agar and eosin methylene blue (EMB) 
agar and incubated at 35°C for 20–22 h. Con-
ventional methods and Vitek 2 Compact System 
(Biomeriux, France) and a BD Phoenix (BD Diag-
nostic Systems, USA) automated system were used 
in the identification of the bacteria. The antibiotic 
susceptibility of the isolates and ESBL production 
of the gram-negative bacteria were analyzed with 
the Vitek 2 Compact System and the BD Phoenix 
automated system. 
Sixty-two VR E. faecium strains detected in 
hospitalized patients were included in the study. 
These isolates were collected by rectal swaps by an 
infection control committee. The rectal swaps were 
inoculated onto VRE screening agar containing 6 
µg/ml of vancomycin and incubated at 35° C for 24 
h. Gram staining, catalase, and pyrolidonly-beta 
naphilamide tests were performed for enterococci-
suspicious  bacteria  for  preidentification. After  the 
preidentification,  final  identification  and  antibiotic 
susceptibility were tested with the Vitek 2 Compact 
System and the BD Phoenix system. 
The Kirby-Bauer disc diffusion method was 
used for the determination of fosfomycin suscepti-
bility using discs (HIMEDIA, India) containing 200 
µg/ml of fosfomycin with 50 μg/ml of D-glucose-6 
phosphate as recommended by the Clinical and 
Laboratory Standards Institute (CLSI).12 The rec-
ommendations of the CLSI for urinary isolates of 
E. feacalis were used to determine the fosfomycin 
susceptibility of gram-positive bacteria, and the disc 
diffusion criteria for urinary tract isolates of E. coli 
recommended by the CLSI were used to identify 
the fosfomycin susceptibility of gram-negative bac-
teria.12
RESULTS
All the enterococcoci isolates from the rectal swap 
specimens were determined as E. faecium, and all 
(n=62) were susceptible to fosfomycin by the disc 
diffusion method. All the MRSA (n=40) and MR-Karadağ A, et al., In vitro efficacy of fosfomycin  57
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CoNS (n=40) isolates were susceptible to fosfomy-
cin. Of the 100 gram-negative bacteria, 55 (55%) 
were ESBL positive. Among the E. coli isolates 39 
(97.5%) of 40 were fosfomycin susceptible. Of 37 K. 
pneumoniae isolates, 36 (97.3%) were susceptible, 
and one (2.7%) showed intermediate susceptibility 
to fosfomycin. Of 23 Enterobacter spp. isolates, 20 
(86.9%) were susceptible to fosfomycin, and three 
(13.1%) showed intermediate susceptibility to fosfo-
mycin (Table 1).
Bacteria Susceptible
n (%)
Intermediate
n (%)
Resistant
n (%)
Total
n (%)
MRSA 40 (100) - - 40 (100)
MRCoNS 40 (100) - - 40 (100)
VR E. faecium 62 (100) - - 62 (100)
E. coli 39 (97.5) - 1 (2.5) 40 (100)
K. pneumoniae 36 (97.3) 1 (2.7) - 37 (100)
Enterobacter spp. 20 (86.9) 3 (13.1) - 23 (100)
Table 1. Fosfomycin susceptibility 
rates of the isolates
DISCUSSION
Fosfomycin trometamol is a form of fosfomycin and 
used orally in a single dose in the treatment of non-
complicated urinary system infections. Fosfomycin 
disodium salt is an intravenous (i.v.) form of fosfo-
mycin and used in some European countries and in 
Japan. Although fosfomycin has not been approved 
for conditions other than urinary system infections, 
successful outcomes were reported in some studies 
that used i.v. fosfomycin for several types of infec-
tions other than those affecting the urinary tract.11,13 
Various treatment regimens, including amino-
glycosides, linezolid, daptomycin and quinupristin-
dalfopristin, have been used in the treatment of 
VRE. However, resistance to these agents was re-
ported.7,14 In this study, we determined that all VR 
E. faecium isolates were susceptible to fosfomycin. 
Allerger et al.15 reported that 96% of VRE were sus-
ceptible to fosfomycin according to the disc diffu-
sion method. In another study, all the VR E. faecalis 
(n=23) and 98.1% of VR E. faecium (51/52) isolates 
were found to be susceptible to fosfomycin.16 Shres-
tha et al.17 reported that only one (1.3%) of 75 VR 
E. faecium isolates isolated from urinary and blood 
culture specimens was resistant to fosfomycin. In 
another study, 98.4% of 193 VR E. faecalis isolates 
were fosfomycin susceptible.7 In a study carried 
out in Turkey, fosfomycin resistance was not deter-
mined in VRE isolates, similar to the results of our 
study.18 
MRSA is considered an important problem in 
both hospital- and community-acquired infections.19 
In a study conducted by Falagas et al.,20 129 of 130 
(99.2%) MRSA isolates and 745 of 961 (77.5%) 
MRCoNS isolates were susceptible to fosfomycin. 
Fosfomycin was found to be effective in the treat-
ment of experimental MRSA osteomyelitis in rats.5 
Synergistic and additive effects were detected fol-
lowing treatment with a combination of fosfomycin 
with linezolide, rifampicin and antistaphylococcal 
beta-lactams.9 Oksuz et al.21 reported high fosfomy-
cin resistance (58%) in isolates of a ST239-MRSA-
III clone, which was the most frequently detected 
clone in their study, and identified fosB in all the iso-
lates of that clone. 
A recent study demonstrated that fosfomycin 
was effective against ESBL-producing Enterobac-
tericeae, particularly E. coli.6 In our study, 97.5% 
of  E. coli isolates were susceptible to fosfomy-
cin. In another study carried out in Turkey, 96.5% 
(332/344) of ESBL- producing E. coli isolates were 
reported to be fosfomycin susceptible.22 Endimiani 
et al.23 found that 63.2% (43/68) of K. pneumoniae 
carbapenemase (KPC)-producing K. pneumoniae 
isolates were susceptible to fosfomycin. In a study 
of the fosfomycin susceptibility of 157 multidrug-
resistant E. coli (89 of which were ESBL produc-
ers) by the disc diffusion method, 99.4% (98.9% of 
ESBL producers) were susceptible to fosfomycin.24 
Tharavichitkul et al.25 reported that 88.4% of ESBL-
producing  K. pneumoniae isolates and 97.3% of 
ESBL-producing  E. coli isolates were susceptible 
to fosfomycin. However, in an investigation of an 
outbreak in 1994, all the ESBL-producing K. pneu-
moniae isolates (n=12) analyzed with the disc diffu-
sion method were fosfomycin resistant.26 In another 
evaluation of an outbreak, of 76 multidrug-resistant 
E.  aerogenes  isolates  identified,  only  3.9%  were 
susceptible to fosfomycin.27 These reports point to 
the possibility of the spread of fosfomycin-resistant 
isolates in hospitals. However, fosfomycin resis-Karadağ A, et al., In vitro efficacy of fosfomycin  58
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tance is not common in daily clinical practice. Demir 
et al.28 reported the resistance to fosfomycin in clini-
cal isolates of E. coli, K. pneumoniae, and Entero-
bacter spp. as 2%, 9.4%, and 4.4%, respectively. 
In our study, 97.3% of K. pneumoniae isolates and 
86.9% of Enterobacter spp. isolates were fosfomy-
cin susceptible. 
According to the CLSI, when testing fosfomy-
cin susceptibility, breakpoint values for agar dilution 
and zone diameters for disc diffusion exist only in 
E. coli and E. faecalis isolates isolated from urinary 
specimens. The agar dilution method is a reference 
method used to determine the minimum inhibitory 
concentration values.12 However, it is time consum-
ing and not easily applicable in daily practice. On 
the other hand, the disc diffusion method is quick 
and easy to apply. As zone diameters and break-
points have not yet been determined for bacteria 
other than E. coli and E. faecalis by the CLSI, there 
is a need for further studies that include numerous 
isolates for determination of both zone diameters 
and breakpoints values.
In conclusion, fosfomycin was found to be high-
ly active against MRSA, MRCoNS, VRE, E. coli, K. 
pneumoniae, and Enterobacter spp. isolates. Fos-
fomycin can be considered an alternative drug for 
the treatment of infections.
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